Skip to content
The Policy VaultThe Policy Vault

Bimzelx (bimekizumab-bkzx)Point32Health

Psoriatic arthritis

Preferred products

  • Cimzia
  • Enbrel
  • Humira
  • Simponi
  • Skyrizi
  • Yesintek
  • Taltz
  • Tremfya
  • Rinvoq
  • Xeljanz

Initial criteria

  • Documented diagnosis of psoriatic arthritis
  • Patient age ≥ 18 years
  • Prescribed by or in consultation with a rheumatologist or dermatologist
  • Documentation of one (1) of the following: a. Trial and failure with two (2), or contraindication to all of the following: Cimzia, Enbrel, Humira, Simponi, Skyrizi, Yesintek, Taltz, Tremfya, Rinvoq, Xeljanz OR b. The patient is new to the plan and stable on Bimzelx and the prescribing physician has documented that changing to a preferred product would result in adverse clinical outcomes